US › Healthcare

Gracell Biotechnologies Inc. (GRCL)

US · Healthcare · Biotechnology

$554.95-1.95%

Last close · 2026-08-04

Latest quarter · ended 2023-09-30

Revenue

Net profit

$-67.6M

Profit YoY

+60.7%

EPS

$-0.10

EPS estimate

$-0.20

EPS came in at -0.10 against a street estimate of -0.20 — a beat of 50.0%.

Key statistics

Market cap

$989.9M

Forward P/E

0.0

P/B

4.39

Book value

$16.90

EPS (TTM)

$-0.97

52-week high

$629.20

52-week low

$306.65

50-day MA

$9.54

200-day MA

$5.24

Beta

-0.34

Analyst view

Analysts rate Gracell Biotechnologies Inc. a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $12.50.

Shareholding

Insiders

16.39%

Institutions

63.11%

Largest institutional holders

Fund	Stake
China Universal Asset Mgmt Co.Ltd	0.01%
PNC Financial Services Group Inc	0.00%
Goldman Sachs Group Inc	0.00%
Gabelli Funds LLC	0.00%
Wells Fargo & Co	0.00%
Pentwater Capital Management LP	0.00%
Temasek Holdings Ltd.	0.00%
Orbimed Advisors, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Gracell Biotechnologies Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.